About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

Treatments > Treatment settings (with abstracts)

Last update: 04/24/2010

TOPICS
First-line maintenance Approaches | Response & Response Duration   
Aggressive Approaches
| Survival

TOPIC SEARCH: First-line | Response & Duration | Survival

Also see Refractory

First-line
maintenance

Return to top

1a. Current treatment of follicular and low-grade non-Hodgkin's lymphoma. Anticancer Drugs. 2001 Jun;12 Suppl 2:S5-9. Review. PMID: 11508934 abstract | Related_abstracts
2a. Quality of life in patients with low-grade non-Hodgkin's lymphoma. 
Oncology (Huntingt). 1998 May;12(5):697-714; discussion 714, 717, 721. Review.
PMID: 9597680 abstract
3a. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial. abstract
4a. Vaccine Therapies for Non-Hodgkin's Lymphoma. Curr Treat Options Oncol. 2002 Aug;3(4):307-15. PMID: 12074767  PubMed

Response & Response Duration

Also see
 Time to Progression

Return to top

1b. Each Subsequent Therapy Results in Diminishing Response Rate and Duration of Response in Low Grade or Transformed Low Grade Non-Hodgkin's Lymphoma.  ASCO 2001 Abstract 1165 
2b. Time to Progression Table  Lymphomation.org
3b. Stage III follicular lymphoma: long-term follow-up and patterns of failure.
Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):748-54  PMID: 14529780

Aggressive approaches
 
with the goal of achieving molecular remissions, long-term disease-free survival, and possible cures

There is hope that the  following types of therapies may cure some patients with indolent NHL in some treatment settings

Note: For aggressive NHL, the goal of initial treatment is to cure.

CHOP + Rituxan
Transplants
Therapeutic vaccines
Radiotherapy
Other combinations

Return to top

1c. Can we cure indolent lymphomas? Clin Cancer Res. 1997 Dec;3(12 Pt 2):2655-9. Review. PMID: 10068269 PubMed
2c. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Semin Oncol. 2002 Feb;29(1 Suppl 2):36-40. PMID: 11842387 PubMed
3c. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15;98(13):3595-9 PubMed
4c. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999 Oct;5(10):1171-7. PMID: 10502821 PubMed
5c. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. Eur J Haematol. 2002 Mar;68(3):144-9. PMID: 12068794  PubMed
6c. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. [in patients with nodal bulky disease] - Eur J Haematol 2002: 68: 144-149  PDF | PDFHelp
7c. Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL. Hematol Oncol. 2003 Sep;21(3):99-108  PMID: 14579238 
8c. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk Lymphoma. 2003 Nov; 44(11): 1911-7  PMID: 14738142 | Related articles

Radiotherapies

1r. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. [in patients with nodal bulky disease] - Eur J Haematol 2002: 68: 144-149  PDF | PDFHelp
2r. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial.
Eur J Haematol. 2002 Mar;68(3):144-9. PMID: 12068794  PubMed
3r. Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer. 1995 May 1;75(9):2361-7. PMID: 7712449  PubMed

Survival & Durable Responses

Return to top

1d. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma.
Acta Oncol. 2001;40(2-3):213-23. Review. PMID: 11441933 abstract
2d. Non-Hodgkin's lymphoma: review of conventional treatments. Curr Pharm Biotechnol. 2001 Dec;2(4):279-91. PMID: 11762410 abstract
3d. Horning S, Rosenberg S: The natural history of initially untreated low-grade non-Hodgkins lymphomas. N Engl J Med 311:1471-1475, 1984.)
4d. The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas 
By Armando López-Guillermo, Fernando Cabanillas, Peter McLaughlin, Terry Smith, Fredrick Hagemeister, María A. Rodríguez, Jorge E. Romaguera, Anas Younes, Andreas H. Sarris, H. Alejandro Preti, William Pugh, and Ming-Seng Lee  
Blood, Vol. 91 No. 8 (April 15), 1998: pp. 2955-2960  bloodjournal.org full text
5d.  The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk Lymphoma. 2003 Nov; 44(11): 1911-7  PMID: 14738142 | Related articles
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.